Evox Therapeutics expands its existing exosome patent portfolio

Evox Therapeutics, a leading exosome therapeutics company, is pleased to announce that the Company has been granted another key patent by the European Patent Office (EPO). This new grant reinforces the Company’s leading position within field of exosome therapeutics and adds to the growing number of foundational patent families within the Evox IP portfolio.

The recently granted European patent (EP3463465) provides coverage for exosomes and methods of producing exosomes comprising an endogenous polypeptide-based release system for enabling luminal loading of soluble proteins inside an exosome. Such a release mechanism is important for optimal functional exosome-mediated delivery of soluble therapeutic proteins and enzymes into recipient cells.

Dr Antonin de Fougerolles, Chief Executive Officer of Evox, commented:

“We are pleased to have been granted another important patent within our rapidly growing therapeutic exosome patent estate. This patent provides broad protection for our internal pipeline programs, where we are using this approach to functionally deliver soluble enzymes into cells in order to correct rare metabolic diseases. It is also broadly applicable to delivery of other types of drug payloads where luminal loading inside an exosome is important.”

Source – PRNewswire

Leave a Reply

Your email address will not be published. Required fields are marked *